Ferring Pharmaceuticals has acquired Cytokine PharmaSciences Inc. (CPSI) and its UK subsidiary Controlled Therapeutics (Scotland) Ltd. (CTS), a global biopharmaceutical company with a particular focus in obstetrics.

“This acquisition advances our vision to become the global scientific and commercial leader in reproductive health, and perfectly complements our already strong portfolio of obstetrics products including TRACTOCILE (atosiban) and PABAL (carbetocin). In addition, the acquisition includes the manufacturing assets for dinoprostone marketed by Forest Laboratories, Inc. as CERVIDIL in the US and Canada, and by Ferring as PROPESS elsewhere. This acquisition gives us the opportunity to integrate the product portfolio into Ferring on a global basis and to extend our presence in this important field,” said Michel Pettigrew, president of the executive board and chief operating officer at Ferring.

CTS has also developed a pipeline of women’s healthcare products, including the misoprostol vaginal insert which is intended to be marketed in the U.S. and Canada as MISODEL and in Europe and the rest of the world as MISOPESS. It is anticipated that the new treatment will be filed for FDA approval in 2012.